Clovis Oncology (CLVS) Misses Q3 EPS by 55c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology Announces Third Quarter 2015 Operating Results
November 5, 2015 4:05 PM ESTNew Drug Application (NDA) for rociletinib for the treatment of advanced EGFR-mutant T790M+ non-small cell lung cancer (NSCLC) on file with U.S. FDA Marketing Authorization Application (MAA) for rociletinib on file in E.U.; action expected mid-2016 Raised $298 million in July equity offering Enrollment now complete in mutant BRCA population required for U.S. NDA submission for rucaparib in advanced ovarian cancer Rucaparib U.S. NDA submission planned Q2 2016 Erle Mast, Clovis Chief... More
